Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 14/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.30 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 2/20 | 0.30 |
| ▸ | MAPK7 | Q13164 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22968962 | 0.85 | RIPK1 (0.36) | RIPK1GABRG2GABRB3GABRA5 | |
| SCHEMBL22968820 | 0.84 | RIPK1 (0.36) | RIPK1GABRG2GABRB3GABRA5BRD4 | |
| SCHEMBL25767292 | 0.82 | RIPK1 (0.32) | RIPK1GABRG2GABRB3GABRA5 | |
| SCHEMBL25767068 | 0.80 | IP6K1 (0.37) | MAPTRIPK1 | |
| SCHEMBL1562222 | 0.78 | AADAT (0.43) | RIPK1LIMK1LIMK2 | |
| SCHEMBL1562220 | 0.78 | AADAT (0.43) | RIPK1LIMK1LIMK2 | |
| SCHEMBL25244084 | 0.76 | MEN1 (0.36) | MAPTRIPK1LIMK1LIMK2 | |
| SCHEMBL25244083 | 0.76 | MEN1 (0.36) | MAPTRIPK1LIMK1LIMK2 | |
| SCHEMBL18227002 | 0.76 | CYP11B2 (0.48) | GABRG2GABRB3GABRA5 | |
| SCHEMBL22968883 | 0.75 | ADORA3 (0.39) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021029632-A1 | FUSED RING HETEROARYL COMPOUNDS AS RIPK1 INHIBITORS | BISICHEM CO., LTD. (KR) | 2021-02-18 | — | — | WO | disclosed |
| US-20210040115-A1 | FUSED RING HETEROARYL COMPOUNDS AS RIPK1 INHIBITORS | BISICHEM CO., LTD. (KR) | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040115-A1 | FUSED RING HETEROARYL COMPOUNDS AS RIPK1 INHIBITORS | RIPK1, RIPK3, RIPK4 | MAPT 130/4885RIPK1 1/4885GABRG2 4574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.